Drug Trial Radar · NCT00160342
Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes
Last checked: Nov 19, 2026Latest source record: Aug 15, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,251
Planned (sponsor's estimate)
Start
Jun 2005
Primary completion
Sep 2007
Study completion Sep 2007
Sponsor
- Lead sponsor
- Solvay PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 45 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a research study to evaluate the effectiveness, safety and side effects of several dose levels of esterified estrogens (EE) and methyltestosterone (MT) given individually and in combination compared to a placebo (a tablet with no active drug in it) as a possible treatment for vasomotor symptoms (such as hot flushes and flushing) of menopause. EE and testosterone are two hormones which are typically deficient in menopausal women
Conditions
- Hot Flushes, Menopause, Postmenopause
Interventions
Esterified Estrogens (EE) and Methyltestosterone (MT)Drug
oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
Esterified Estrogens (EE) and Methyltestosterone (MT)Drug
oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
Esterified Estrogens (EE) and Methyltestosterone (MT)Drug
oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
Esterified Estrogens (EE) and Methyltestosterone (MT)Drug
oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
Esterified Estrogens (EE) and Methyltestosterone (MT)Drug
oral tablet, QD, 12 weeks, 0.30 EE
Esterified Estrogens (EE) and Methyltestosterone (MT)Drug
oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
Esterified Estrogens (EE) and Methyltestosterone (MT)Drug
oral tablet, QD, 12 weeks, 0.45 EE
Esterified Estrogens (EE) and Methyltestosterone (MT)Drug
oral tablet, QD, 12 weeks, 0.60 MT
Esterified Estrogens (EE) and Methyltestosterone (MT)Drug
oral tablet, QD, 12 weeks, Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in frequency of moderate to severe vasomotor symptoms (VMS) from baseline to Week 4Time frame: 4 weeks
- Mean change in frequency of moderate to severe VMS from baseline to Week 12Time frame: 12 weeks
- Mean change in severity of moderate to severe VMS from baseline to Week 4Time frame: 4 weeks
- Mean change in severity of moderate to severe VMS from baseline to Week 12Time frame: 12 weeks
Locations
125 sites in 3 countries. Site status is shown where the registry gives one.
Site 37
Montgomery, Alabama
Site 69
Montgomery, Alabama
Site 44
Tucson, Arizona
Site 6
Jonesboro, Arkansas
Site 62
Little Rock, Arkansas
Site 70
Carmichael, California
Site 85
Carmichael, California
Site 87
Northridge, California
Site 18
San Diego, California
Site 27
San Diego, California
Site 54
San Diego, California
Site 31
Vista, California
Site 68
Walnut Creek, California
Site 66
Denver, Colorado
Site 4
Groton, Connecticut
Site 35
New Britain, Connecticut
Site 14
Waterbury, Connecticut
Site 25
Aventura, Florida
Site 26
Aventura, Florida
Site 51
Clearwater, Florida
Site 71
Clearwater, Florida
Site 61
Daytona Beach, Florida
Site 75
Gainesville, Florida
Site 33
Pensacola, Florida
Site 21
Stuart, Florida
Site 82
Tampa, Florida
Site 9
Venice, Florida
Site 83
West Palm Beach, Florida
Site 40
Alpharetta, Georgia
Site 90
Alpharetta, Georgia
Site 23
Atlanta, Georgia
Site 8
Atlanta, Georgia
Site 60
Powder Springs, Georgia
Site 55
Savannah, Georgia
Site 76
Boise, Idaho
Site 64
Champaign, Illinois
Site 58
Chicago, Illinois
Site 72
Chicago, Illinois
Site 74
Chicago, Illinois
Site 50
Evansville, Indiana
Showing 40 of 125 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.